Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 5 von insgesamt 5
- Rekrutierung läuftRadiation during Osimertinib Treatment: a Safety and Efficacy Cohort studyMolekulare Marker
- Rekrutierung läuftFirst Line Ipilimumab+Nivolumab Combined with two cycles of Chemotherapy in NSCLC [FINN]
- Rekrutierung läuftMaster Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors (BZKF-Studie)
- Rekrutierung läuftA Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9)Molekulare Marker
- Rekrutierung läuft
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]
Molekulare Marker